Biotechnology companies already burdened with funding treatments nearing market approval are entering into agreements with private-equity firms to create separate entities to help shoulder the risk and cost associated with developing promising early-stage drugs. This financing mechanism fell out of favor amid some scandals involving off-balance sheet arrangements, but the new deals are transparent and the entities' financial dealings are covered in the parent company's statements.

Related Summaries